Stock Price Quote

ZYDUS LIFESCIENCES LTD.

NSE : ZYDUSLIFEBSE : 532321ISIN CODE : INE010B01027Industry : Pharmaceuticals & DrugsHouse : Cadila
BSE1105.657.75 (+0.71 %)
PREV CLOSE ( ) 1097.90
OPEN PRICE ( ) 1096.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 28522
TODAY'S LOW / HIGH ( )1091.40 1110.00
52 WK LOW / HIGH ( )835.85 1119
NSE1105.907.6 (+0.69 %)
PREV CLOSE( ) 1098.30
OPEN PRICE ( ) 1095.00
BID PRICE (QTY) 1105.90 (90)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 728343
TODAY'S LOW / HIGH( ) 1091.20 1110.40
52 WK LOW / HIGH ( )835.5 1119.8
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 15-05 1995
Management Info
Pankaj R Patel - Chairman Sharvil P Patel - Managing Director
Registered Office

Address Zydus Corporate Park, Scheme No.63,Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle,Sarkhej - Gandhinagar Highway,
Ahmedabad,
Gujarat-382481

Phone 079-71800000 / 48040000

Email dhavalsoni@zyduscadila.com

Website www.zyduscadila.com

Registrars Details
MUFG Intime India Pvt Ltd.
506-508, 5th Floor, Amaranth Business Complex - I (ABC - I),Beside Gala Business Center, St. Xaviers Corner, Off C.G. Road,Navrangpura,Ahmedabad
Listing : BSE, NSE

NEWS

20May Zydus Lifesciences soars on reporting
Zydus Lifesciences is currently trading at Rs. 1077.35, up by 58.40 poin..
19May Zydus Lifesciences reports 9% rise in
Zydus Lifesciences has reported results for the fourth quarter (Q4FY26)..
19May Zydus Lifesciences informs about inve
Pursuant to the provisions of regulation 30 read with regulation 46 of t..
19May Zydus Lifesciences informs about outco
Zydus Lifesciences has informed that the Board of Directors at their mee..
19May General Update On Buyback
Intimation about intention of promoters to participate in buyback

Financials

in Millions
QTR Mar 26 ANNUAL 26
Net Profit1722035598
Gross Profit 21110 43819
Operating Profit 2484255929
Net Sales 37409114840

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Torrent Pharma (BSE)
peergroup  4570.00 (2.39%)
M.Cap ( in Cr)154669.57
Wockhardt (BSE)
peergroup  1927.00 (5.14%)
M.Cap ( in Cr)31312.24
RPG Life Sciences (BSE)
peergroup  2200.25 (4.27%)
M.Cap ( in Cr)3639.00
Venus Remedies (BSE)
peergroup  1716.45 (5.00%)
M.Cap ( in Cr)2294.38
Ajanta Pharma (BSE)
peergroup  3140.05 (2.19%)
M.Cap ( in Cr)39230.41

Shareholding Pattern

PROMOTERS 75%
NON-INSTITUTION 6.86%
FI/BANKS/INSURANCE 6.14%
MUTUAL FUNDS/UTI 4.88%
GOVERNMENT 0%
FII 0%

About Zydus Lifesciences Ltd.

Zydus Lifesciences Ltd. was incorporated in the year 1995. Its today's share price is 1105.65. Its current market capitalisation stands at Rs 111254.26 Cr. In the latest quarter, company has reported Gross Sales of Rs. 151295 Cr and Total Income of Rs.160472 Cr. The company's management includes Mukesh M Patel, Ganesh N Nayak, Sharvil P Patel, Upasana Konidela, Akhil Monappa, Shelina P Parikh, Bhadresh K Shah, Pankaj R Patel, Dhaval N Soni.

It is listed on the BSE with a BSE Code of 532321 , NSE with an NSE Symbol of ZYDUSLIFE and ISIN of INE010B01027. It's Registered office is at Zydus Corporate Park, Scheme No.63,Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle,Sarkhej - Gandhinagar HighwayAhmedabad-382481, Gujarat. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Deloitte Haskins & Sells LLP, Mukesh M Shah & Co, RR Patel & Co

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.